TITLE

Shire to Merge with Roberts Via $1 Billion Stock Transaction

PUB. DATE
September 1999
SOURCE
Worldwide Biotech;Sep99, Vol. 11 Issue 9, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the merger agreement of Shire Pharmaceuticals PLC and Roberts Pharmaceutical Corporation. Comments from Rolf Stahel, chief executive officer (CEO) of Shire and John Spitznagel, CEO of Roberts; Approval from Yamanouchi Pharmaceutical Company Ltd. and Healthcare Ventures of the merger deal.
ACCESSION #
2219618

 

Related Articles

  • Shire Pharmaceuticals Acquires Roberts. Scheraga, Dan // Chemical Market Reporter;08/02/99, Vol. 256 Issue 5, p3 

    Announces the acquisition of Roberts Pharmaceutical Corp. by Shire Pharmaceuticals company. Estimated value of the acquisition; Details on the business of both companies; Revenues posted by the two companies during the first half of 1999; Popular drug developed by Shire.

  • Shire to buy Roberts for $1.07 billion.  // Medical Marketing & Media;Sep99, Vol. 34 Issue 9, p28 

    Reports on England-based drug company Shire Pharmaceuticals Group's acquisition of Roberts Pharmaceutical Corp., a New Jersey-based manufacturer of drugs for low blood pressure and blood clots.

  • In a rare deal, Shire buys Dyax.  // TCE: The Chemical Engineer;Dec2015/Jan2016, Issue 894/895, p7 

    The article reports that Irish pharmaceutical firm Shire Pharmaceuticals Group PLC has acquired rare diseases treatment specialist Dyax Corp. as part of efforts to be a top biotechnology company as of December 2015.

  • Shire Pays $260M for Lumena in Latest Pharma Deal. Collins, Allison // Mergers & Acquisitions Report;5/19/2014, Vol. 29 Issue 20, p7 

    The article reports pharmaceutical company Shire's 260 million dollar-acquisition of Lumena, a liver diseases and metabolic disorders drug developer. It mentions that Lumena was sold by RiverVest Venture Partners which invested on it for 75 million dollars back in 2006. It also cites other...

  • Shire bags NPS, including newly approved biologic for hypoparathyroidism.  // Nature Biotechnology;Mar2015, Vol. 33 Issue 3, p226 

    The article reports on the acquisition of Bedminster, New Jersey-based NPS Pharmaceuticals Inc. by Dublin, Ireland-based Shire Pharmaceuticals Group PLC. The move aims to expand Shire's market reach in rare gastrointestinal and endocrine diseases and build on its manufacturing infrastructure in...

  • Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drugs.  // Mergers & Acquisitions Report;11/18/2013, Vol. 28 Issue 46, p6 

    The article reports that Shire PLC purchased ViroPharma for 4.2 billion for additional drugs into the pharmaceutical portfolio of the former. The deal enabled Shire to add attention deficit hyperactivity disorder drug Vyvanse and angioedema drug Cinryze. The purchase was the third for Shire...

  • Acquisitions keep pharma in shape. Mirasol, Feliza // ICIS Chemical Business Americas;3/12/2007, Vol. 271 Issue 10, p35 

    The article deals with mergers in the pharmaceutical industry as of March 2007. It is noted that the buyout of Hypnion by Eli Lilly and acquisition of New River Pharmaceuticals by Shire Pharmaceuticals reflect that drug companies are focusing on investing more into their research and development...

  • Assets for Advantage. Looney, William // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p10 

    An introduction to the journal is presented in which the editor discusses an article on the survey from Hay Group on Sales Force Effectiveness, the profile of Shire Pharmaceuticals Group PLC, and the fourth annual choice of the Drug Brand of the Year.

  • INTUNIV.  // Physician Assistants' Prescribing Reference;Winter2009, Vol. 16 Issue 4, pA19 

    The article evaluates the medicine Intuniv from Shire Pharmaceuticals Group PLC.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics